Disclosed herein are pharmaceutical compositionscomprising Abiraterone acetate and Darolutamide, which are usefulin the treatment of a type of prostate cancer. The pharmaceuticalcomposition possesses increased in- vitro permeability both in fasted andfed state which allows significant dose reduction and the abandoningof the requirement of taking the drugs on an empty stomach. Furtherdisclosed are methods of formulating and manufacturing the pharmaceuticalcomposition, its uses and methods of treatment using thepharmaceutical composition.
